Search Result

Results for "

γ-secretase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	γ-secretase (59) Amyloid-β (11) Apoptosis (9) Autophagy (1) Notch (12) Organoid (2) Proteasome (2)
By Research Areas:	Cancer (21) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (50)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: γ-secretase Beta-secretase Legumain

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148306

γ-Secretase modulator 14	γ-secretase	Neurological Disease
γ-Secretase modulator 14 is a *γ-secretase* modulator. γ-Secretase modulator 14 has the potenial for Alzheimer's disease (AD) research (WO2013010904A1; compound 42) .

HY-146151

γ-Secretase modulator 12	γ-secretase Amyloid-β	Neurological Disease
γ-Secretase modulator 12 (Compound 1a) is a *γ-secretase* modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC₅₀ of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice .

HY-145372

γ-Secretase modulator 10

γ-secretase Neurological Disease

γ-Secretase modulator 10 is a novel γ-secretase modulator.

γ-Secretase modulator 10	γ-secretase	Neurological Disease
γ-Secretase modulator 10 is a novel *γ-secretase* modulator.

HY-147720A

γ-Secretase modulator 11 hydrochloride	γ-secretase	Neurological Disease
γ-Secretase modulator 11 hydrochloride (compound 1o) is a potent and orally active *γ-secretase* modulator with an IC₅₀ of 0.029 µM. γ-Secretase modulator 11 hydrochloride induces a robust reduction in brain Aβ42 levels. γ-Secretase modulator 11 hydrochloride rescues cognitive deficits exhibited by AD model mice. γ-Secretase modulator 11 hydrochloride has the potential for the research of alzheimer's disease .

HY-150049

γ-Secretase modulator 13	Amyloid-β	Neurological Disease
γ-Secretase modulator 13 (compound 4) is a gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 163 nM. γ-Secretase modulator 13 can be used in the study of Alzheimer's disease .

HY-128581

γ-Secretase modulator 4	γ-secretase	Neurological Disease
γ-Secretase modulator 4 is a potent *γ-secretase* modulator, reduces the Aβ42 level with IC₅₀s of 0.014 μM and 0.017 μM in human and mouse, respectively .

HY-12465

Z-Ile-Leu-aldehyde 2 Publications Verification Z-IL-CHO; GSI-XII; γ-secretase inhibitor XII	Notch γ-secretase Apoptosis	Cancer
Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of *γ-secretase* and notch .

HY-50900

gamma-Secretase Modulators Amyloid-β production inhibitor; γ-secretase Modulators	Amyloid-β	Neurological Disease
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.

HY-14176

Compound E 5+ Cited Publications γ-secretase-IN-1	γ-secretase	Cancer
Compound E is a *γ-secretase* inhibitor. Compound E bloks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-147720

γ-Secretase modulator 11	γ-secretase	Neurological Disease
5-{8-[(3,4'- difluoro [1,1'- biphenyl]-4-yl) methoxy] - 2-methylimidazo [1,2-a] pyridin-3-yl}-n-methylpyridin-2-formamide (1o) showed high potency in vitro and brain exposure, inducing brain a β 42 levels were significantly reduced and showed undetectable inhibition of cytochrome P450 enzymes. In addition, compound 1o showed excellent anti cognitive deficit effect in AD model mice.

HY-10043

gamma-secretase modulator 1

γ-secretase Neurological Disease

γ-secretase inhibitior-1 is a gamma-secretase modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease.

gamma-secretase modulator 1	γ-secretase	Neurological Disease
γ-secretase inhibitior-1 is a gamma-secretase modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease.

HY-50754

gamma-secretase modulator 2	γ-secretase	Neurological Disease
gamma-secretase modulator 2 is a potent and selective γ-secretase modulator for treatment of Alzheimer's disease IC50 value: Target: γ-secretase γ-secretase modulator is modulation of the action of γ-secretase so as to Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain.

HY-10043A

gamma-secretase modulator 1 hydrochloride	γ-secretase	Neurological Disease
gamma-secretase inhibitior-1 is a *gamma-secretase* modulator, γ-secretase inhibitior-1 is useful for Alzheimer's disease .

HY-50889

gamma-secretase modulator 3

γ-secretase Neurological Disease

gamma-secretase modulator 3 is a gamma-secretase modulator.

gamma-secretase modulator 3	γ-secretase	Neurological Disease
gamma-secretase modulator 3 is a gamma-secretase modulator.

HY-150050

gamma-secretase modulator 5	Amyloid-β	Neurological Disease
gamma-secretase modulator 5 (compound 22d) is a brain-penetrant gamma-secretase modulator (GSMs) that inhibits the production of the aggregated amyloid β-peptide Aβ42 with an IC₅₀ value of 60 nM. gamma-secretase modulator 5 can be used in the study of Alzheimer's disease .

HY-15185

Nirogacestat 5+ Cited Publications PF-3084014; PF-03084014	γ-secretase Apoptosis	Cancer
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective *γ-secretase* inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-15185B

Nirogacestat dihydrobromide 5+ Cited Publications PF-3084014 dihydrobromide; PF-03084014 dihydrobromide	γ-secretase Apoptosis	Cancer
Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective *γ-secretase* inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-N2319

Dihydroergocristine mesylate DHEC mesylate
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-18614

LY900009	Notch γ-secretase	Cancer
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC₅₀ range: 0.005-20 nM). LY900009 can be used for advanced cancer research .

HY-136866

Aβ42-IN-2	γ-secretase	Neurological Disease
Aβ42-IN-2 is a *γ-secretase* modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC₅₀ of 6.5 nM for Αβ₄₂. Aβ42-IN-2 can be used for the research of Alzheimer's disease .

HY-N2319R

Dihydroergocristine mesylate (Standard) DHEC mesylate (Standard)	Amyloid-β	Neurological Disease
Dihydroergocristine (mesylate) (Standard) is the analytical standard of Dihydroergocristine (mesylate). This product is intended for research and analytical applications. Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-50752A

LY-411575 isomer 1

γ-secretase Neurological Disease

LY-411575 isomer 1 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
HY-50884

BMS 433796

γ-secretase Neurological Disease

BMS 433796 is a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease.
HY-50752B

LY-411575 (isomer 2)

γ-secretase Neurological Disease

LY-411575 isomer 2 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
HY-50752C

LY-411575 (isomer 3)

γ-secretase Neurological Disease

LY-411575 isomer 3 is an isomer of LY411575, which is a potent γ-secretase inhibitor.
HY-108714

NGP555

γ-secretase Neurological Disease

NGP555 is a γ-secretase modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .

LY-411575 isomer 1	γ-secretase	Neurological Disease
LY-411575 isomer 1 is an isomer of LY411575, which is a potent γ-secretase inhibitor.

BMS 433796	γ-secretase	Neurological Disease
BMS 433796 is a *γ-secretase* inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer's disease.

LY-411575 (isomer 2)	γ-secretase	Neurological Disease
LY-411575 isomer 2 is an isomer of LY411575, which is a potent γ-secretase inhibitor.

LY-411575 (isomer 3)	γ-secretase	Neurological Disease
LY-411575 isomer 3 is an isomer of LY411575, which is a potent γ-secretase inhibitor.

NGP555	γ-secretase	Neurological Disease
NGP555 is a *γ-secretase* modulator. NGP555 Lowers the Amyloid Biomarker Aβ42 .

HY-50882

ELN318463	γ-secretase	Neurological Disease
ELN318463 is an amyloid precursor protein (APP) selective *γ-secretase* inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12 nM and 656 nM for PS1 and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .

HY-B1786

Sulindac sulfide

cis-Sulindac sulfide

Sulindac sulfide is a noncompetitive γ-secretase inhibitor, with an IC₅₀ of 20.2 μM for γ₄₂-secretase activity.

Sulindac sulfide cis-Sulindac sulfide
Sulindac sulfide is a noncompetitive *γ-secretase* inhibitor, with an IC₅₀ of 20.2 μM for γ₄₂-secretase activity.

HY-50882A

ELN318463 racemate	γ-secretase	Neurological Disease
ELN318463 racemate is the racemate of ELN318463. ELN318463 is an amyloid precursor protein (APP) selective *γ-secretase* inhibitor. ELN318463 shows differential inhibition of presenilin (PS1)- and PS2-comprised γ-secretase with EC₅₀s of 12nM and 656 nM for PS1and PS2, respectively. ELN318463 is 51-fold more selective for PS1 .

HY-14176A

(1R,3S)-Compound E	Others	Cancer
(1R,3S)-Compound E is the isomer of Compound E (HY-14176), and can be used as an experimental control. Compound E is a *γ-secretase* inhibitor. Compound E bloks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-13526

YO-01027 3 Publications Verification Dibenzazepine; DBZ	Notch γ-secretase	Cancer
YO-01027 (Dibenzazepine;DBZ) is a potent *γ-secretase* inhibitor with IC₅₀ values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.

HY-12449

Crenigacestat 4 Publications Verification LY3039478	Notch γ-secretase	Cancer
Crenigacestat (LY3039478) is an orally active Notch and *γ-secretase* inhibitor, with an IC₅₀ of 1 nM in most of the tumor cell lines tested .

HY-50883

BMS 299897	γ-secretase	Neurological Disease
BMS 299897 is a sulfonamide *γ-secretase* inhibitor with an IC₅₀ of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP).

HY-19369

L-685458 3 Publications Verification L-685,458	γ-secretase Apoptosis	Neurological Disease Cancer
L-685458 is a potent transition state analog (TSA) *γ-secretase* inhibitor (GSI). L-685458 inhibits amyloid β-protein precursor γ-secretase activity with IC₅₀ of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L685458 inhibits γ-secretase-mediated cleavage of APP-C99 and Notch-100 with IC₅₀s of 301.3 nM and 351.3 nM, respectively. L-685458 can be used for the research of alzheimer’s disease (AD) and cancers .

HY-119165

GSM-1

γ-secretase Neurological Disease

GSM-1 is a potent γ-secretase modulator. GSM-1 directly targets the transmembrane domain (TMD) 1 of presenilin 1 (PS1) .

GSM-1	γ-secretase	Neurological Disease
GSM-1 is a potent *γ-secretase* modulator. GSM-1 directly targets the transmembrane domain (TMD) 1 of presenilin 1 (PS1) .

HY-111360

SPL-707	γ-secretase	Inflammation/Immunology
SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC₅₀ of 77 nM for hSPPL2a. SPL-707 inhibits *γ-secretase* (IC₅₀=6.1 μM) and SPP (IC₅₀=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells .

HY-15670

BMS-906024 2 Publications Verification	γ-secretase Notch	Cancer
BMS-906024 is an orally active and selective **γ-secretase (gamma secretase) inhibitor. BMS-906024 is a potent pan-Notch receptors inhibitor with IC₅₀**s of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, -2, -3, and -4 receptors, respectively. BMS-906024 demonstrates broad-spectrum antineoplastic activity .

HY-50752

LY-411575 10+ Cited Publications	Organoid γ-secretase Notch Apoptosis	Neurological Disease
LY-411575 is a potent *γ-secretase* inhibitor with IC₅₀ of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with IC₅₀ of 0.39 nM.

HY-B1786S

Sulindac sulfide-d3 cis-Sulindac sulfide-d₃	γ-secretase	Neurological Disease
Sulindac sulfide-d₃ is deuterium labeled Sulindac sulfide. Sulindac sulfide is a noncompetitive γ-secretase inhibitor, with an IC50 of 20.2 μM for γ42-secretase activity.

HY-109174

Fosciclopirox CPX-POM	γ-secretase	Metabolic Disease Cancer
Fosciclopirox suppresses growth of urothelial cancer by targeting the *γ-secretase* complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract . Ciclopirox has anticancer activity in a number of solid and hematologic malignancies.

HY-103538

JLK-6	Amyloid-β	Neurological Disease
JLK-6 markedly reduce the production of amyloid β-peptide (Aβ) by amyloid-β Precursor protein (APP) expressing HEK293 cells by affecting the γ-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor .

HY-13027G

DAPT GSI-IX	γ-secretase	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) (GMP) is DAPT (HY-13027) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DAPT is a potent and orally active *γ-secretase* inhibitor .

HY-18236

MDL-28170 5+ Cited Publications Calpain Inhibitor III	Proteasome	Neurological Disease Inflammation/Immunology
MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration . MDL-28170 also block γ-secretase .

HY-103537

(Rac)-BIIB042	γ-secretase Amyloid-β	Neurological Disease
(Rac)-BIIB042 (Compound 10) is an modulator of *γ-Secretase. (Rac)-BIIB042 reduces Amyloid-β 42* level with an EC₅₀ value of 0.39 µM. (Rac)-BIIB042 can be used for the study of Alzheimer's disease .

HY-B1786A

(E/Z)-Sulindac sulfide	γ-secretase Amyloid-β	Neurological Disease
(E/Z)-Sulindac sulfide is a potent *γ-secretase* modulator (GSM). (E/Z)-Sulindac sulfide selectively reduces Aβ42 production in favor of shorter Aβ species. (E/Z)-Sulindac sulfide can be used for researching Alzheimer’s disease .

HY-13526G

YO-01027 Dibenzazepine; DBZ	Notch γ-secretase	Cancer
YO-01027 (Dibenzazepine) (GMP) is YO-01027 (HY-13526) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. YO-01027 is a potent *γ-secretase* inhibitor .

HY-109174A

Fosciclopirox disodium CPX-POM disodium	γ-secretase	Metabolic Disease Cancer
Fosciclopirox disodium suppresses growth of urothelial cancer by targeting the *γ-secretase* complex. Fosciclopirox disodium selectively delivers the active metabolite, Ciclopirox (HY-B0450), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies .

HY-145428

BT-GSI	Notch γ-secretase	Cancer
BT-GSI is a *γ-secretase* inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression .

HY-120234

Z-LLNle-CHO Z-Leu-Leu-Nle-CHO; GSII	γ-secretase Proteasome Apoptosis	Cancer
Z-LLNle-CHO (Z-Leu-Leu-Nle-CHO) is a *γ-secretase* inhibitor I. Z-LLNle-CHO induces caspase and ROS-dependent apoptosis by blocking the Akt-mediated pro-survival pathway. Z-LLNle-CHO can be used in cancer research, such as breast cancer and leukaemia .

HY-10009

Semagacestat 10+ Cited Publications LY450139	γ-secretase Amyloid-β Notch	Neurological Disease
Semagacestat is a *γ-secretase* inhibitor, inhibits β-amyloid (Aβ42), Aβ38 and Aβ40 with IC₅₀s of 10.9, 12 and 12.1 nM, respectively; also inhibits Notch signaling with IC₅₀ of 14.1 nM. Semagacestat can be used for the research of alzheimer's disease .

Cat. No.	Product Name

HY-L013

Neuronal Signaling Compound Library

2542 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 2542 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

HY-L017

Stem Cell Signaling Compound Library

1740 compounds

Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.

MCE owns a unique collection of 1740 compounds that can be used for stem cell regulatory and signaling pathway research.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote